UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 76

Sortiert nach

Mortality in Dialysis Patients: Analysis of the Causes of Death

American journal of kidney diseases, 1991-09, Vol.18 (3), p.326-335

1991

Volltextzugriff (PDF)

Predictors of survival in patients undergoing dialysis

The American journal of medicine, 1988-05, Vol.84 (5), p.855-862

1988

Volltextzugriff (PDF)

The effects of moderate doses of megestrol acetate on nutritional status and body composition in a hemodialysis patient

Journal of renal nutrition, 1999-04, Vol.9 (2), p.89-94

1999

Volltextzugriff (PDF)

The role of pharmaceutical agents in appetite stimulation in patients with end-stage renal disease

Journal of Renal Nutrition, 1996-07, Vol.6 (3), p.127-133

1996

Volltextzugriff (PDF)

Plasma Angiotensins in Anephric Humans: Evidence for an Extrarenal Angiotensin System

Journal of cardiovascular pharmacology, 1991-03, Vol.17 (3), p.419-423

1991

Volltextzugriff (PDF)

Death by withdrawal from dialysis: a 20-year clinical experience

Journal of the American Society of Nephrology, 1993-03, Vol.3 (9), p.1631-1637

1993

Volltextzugriff (PDF)

Factors influencing job retention for patients with end-stage renal disease

Archives of physical medicine and rehabilitation, 1994-06, Vol.75 (6), p.723

1994

Volltextzugriff (PDF)

PUlmonary embolism Low incidence in chronic renal failure

Archives of internal medicine (1960), 1982-09, Vol.142 (9), p.1646

1982

Volltextzugriff (PDF)

Serum erythropoietin levels and hematocrit in end-stage renal disease: influence of the mode of dialysis

American journal of kidney diseases, 1988-09, Vol.12 (3), p.208-213

1988

Volltextzugriff (PDF)

Blood Pressure Measurement in the Hemodialysis Setting

Advances in renal replacement therapy, 1997-04, Vol.4 (2), p.174-178

1997

Volltextzugriff (PDF)

Normalization of hematocrit in a uremic patient receiving hemodialysis: Role of erythropietin

The Journal of pediatrics, 1983, Vol.103 (1), p.80-83

1983

Volltextzugriff (PDF)

The approach to the treatment of hypertensive patients with renal parenchymal disease

Bulletin of the New York Academy of Medicine (1925), 1982-03, Vol.58 (2), p.170-177

1982

Volltextzugriff (PDF)

Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges

Cell stem cell, 2018-06, Vol.22 (6), p.810-823

2018

Volltextzugriff (PDF)

Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti‐LFA‐1 Antibody Efalizumab

American journal of transplantation, 2010-08, Vol.10 (8), p.1870-1880

2010

Volltextzugriff (PDF)

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

The New England journal of medicine, 2019-08, Vol.381 (7), p.603-613

2019

Volltextzugriff (PDF)

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

Science translational medicine, 2015-11, Vol.7 (315), p.315ra189

2015

Volltextzugriff (PDF)

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Diabetes (New York, N.Y.), 2013-11, Vol.62 (11), p.3766-3774

2013

Volltextzugriff (PDF)

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

The lancet. Diabetes & endocrinology, 2013-12, Vol.1 (4), p.306-316

2013

Volltextzugriff (PDF)

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

Diabetes (New York, N.Y.), 2012-09, Vol.61 (9), p.2340-2348

2012

Volltextzugriff (PDF)

Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo

The Journal of experimental medicine, 2012-09, Vol.209 (10), p.1713-1722

2012

Volltextzugriff (PDF)

Innate immunity and intestinal microbiota in the development of Type 1 diabetes

Nature, 2008-10, Vol.455 (7216), p.1109-1113

2008

Volltextzugriff (PDF)

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

Clinical immunology (Orlando, Fla.), 2009-08, Vol.132 (2), p.166-173

2009

Volltextzugriff (PDF)

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

The Journal of experimental medicine, 2006-07, Vol.203 (7), p.1701-1711

2006

Volltextzugriff (PDF)

How Does Type 1 Diabetes Develop?: The Notion of Homicide or β-Cell Suicide Revisited

Diabetes (New York, N.Y.), 2011-05, Vol.60 (5), p.1370-1379

2011

Volltextzugriff (PDF)

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial

Diabetologia, 2016-06, Vol.59 (6), p.1153-1161

2016

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Englisch
(76)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Humans
(41)
Science & Technology
(38)
Life Sciences & Biomedicine
(36)
Male
(23)
Female
(20)
Adult
(18)
Biological And Medical Sciences
(18)
Adolescent
(16)
Medical Sciences
(16)
Middle Aged
(14)
Animals
(13)
Mice
(13)
Immunology
(11)
Type 1 Diabetes
(11)
Child
(10)
Diabetes Mellitus, Type 1 - Drug Therapy
(9)
Diabetes. Impaired Glucose Tolerance
(9)
Endocrine Pancreas. Apud Cells
(9)
Endocrinopathies
(9)
Etiopathogenesis. Screening. Investigations. Target Tissue Resistance
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mortality in Dialysis Patients: Analysis of the Causes of Death

Predictors of survival in patients undergoing dialysis

The effects of moderate doses of megestrol acetate on nutritional status and body composition in a hemodialysis patient

The role of pharmaceutical agents in appetite stimulation in patients with end-stage renal disease

Plasma Angiotensins in Anephric Humans: Evidence for an Extrarenal Angiotensin System

Death by withdrawal from dialysis: a 20-year clinical experience

Factors influencing job retention for patients with end-stage renal disease

PUlmonary embolism Low incidence in chronic renal failure

Serum erythropoietin levels and hematocrit in end-stage renal disease: influence of the mode of dialysis

Blood Pressure Measurement in the Hemodialysis Setting

Normalization of hematocrit in a uremic patient receiving hemodialysis: Role of erythropietin

The approach to the treatment of hypertensive patients with renal parenchymal disease

Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges

Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti‐LFA‐1 Antibody Efalizumab

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo

Innate immunity and intestinal microbiota in the development of Type 1 diabetes

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

How Does Type 1 Diabetes Develop?: The Notion of Homicide or β-Cell Suicide Revisited

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial

Suchergebnisse filtern